Clinical and Therapeutic Evaluation of the Infection by HIV/AIDS

Boehringer Ingelheim

Status: Completed

Conditions: Acquired Immunodeficiency Syndrome

Treatments: Drug: Nevirapine (Viramune®)

Study type: Observational

Funder types: Industry

Identifiers

NCT02191215

1100.1457

Details and patient eligibility

About

The aim of the Post Marketing Study (PMS) is to evaluate the efficacy and safety profile of nevirapine in the management of the HIV/AIDS in an open environment.

Enrollment: 442 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• diagnosis of HIV/AIDS, no age limits
• patients could be naïve to treatment or pretreated with other antiretroviral agents

Exclusion criteria

• Patients with known hypersensitivity to nevirapine or any other component of the product

Trial design

442 participants in 1 patient group

Nevirapine (Viramune®)

Treatment:

Drug: Nevirapine (Viramune®)